MetLife (MET) Upgraded by ValuEngine to “Buy”

MetLife (NYSE:MET) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Thursday.

A number of other research analysts also recently weighed in on the company. Credit Suisse Group began coverage on MetLife in a research note on Wednesday. They issued an “outperform” rating and a $67.00 price target on the stock. Sandler O’Neill set a $47.00 price target on MetLife and gave the company a “hold” rating in a research note on Thursday, April 5th. Morgan Stanley cut their price target on MetLife from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 5th. Zacks Investment Research raised MetLife from a “sell” rating to a “hold” rating in a research note on Tuesday, April 3rd. Finally, Bank of America began coverage on MetLife in a research note on Monday, March 26th. They issued a “neutral” rating and a $50.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $57.63.

How to Become a New Pot Stock Millionaire

NYSE:MET opened at $47.83 on Thursday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.15 and a current ratio of 0.15. The firm has a market cap of $49,136.88, a price-to-earnings ratio of 10.63, a PEG ratio of 0.84 and a beta of 1.24. MetLife has a 52-week low of $43.38 and a 52-week high of $55.91.

MetLife (NYSE:MET) last posted its quarterly earnings results on Tuesday, February 13th. The financial services provider reported $0.64 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.05 by ($0.41). The company had revenue of $15.79 billion during the quarter, compared to analyst estimates of $15.89 billion. MetLife had a net margin of 5.69% and a return on equity of 8.59%. During the same period last year, the company earned $1.28 EPS. analysts expect that MetLife will post 4.91 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Dallas Securities Inc. bought a new stake in shares of MetLife in the 4th quarter valued at $111,000. Wagner Wealth Management LLC bought a new stake in shares of MetLife in the 4th quarter valued at $126,000. Sandy Spring Bank increased its position in shares of MetLife by 495.2% in the 4th quarter. Sandy Spring Bank now owns 2,375 shares of the financial services provider’s stock valued at $120,000 after buying an additional 1,976 shares in the last quarter. Avestar Capital LLC bought a new stake in shares of MetLife in the 4th quarter valued at $135,000. Finally, Premia Global Advisors LLC bought a new position in MetLife during the 4th quarter worth about $170,000. Institutional investors and hedge funds own 77.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “MetLife (MET) Upgraded by ValuEngine to “Buy”” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/26/metlife-met-upgraded-by-valuengine-to-buy.html.

MetLife Company Profile

MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for MetLife (NYSE:MET)

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply